PBRM1 and lung adenocarcinoma: In addition, mutations in PBRM1 were also found predictive for worse clinical outcomes after PD-L1 blockade in various cancers, including clear cell renal cell carcinoma and lung adenocarcinoma, highlighting the ambiguous role of PBRM1 in immunity [86].